Granted Patent
B2
US 12,539,291 · App. 17/996,413 · Granted Feb 3, 2026
Method of treating affective disorders and personality disorders
Assignee:
HB BIOTECH, INC.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
As described below, the present invention features compositions and methods for treating brain and/or behavioral health disorders and their associated symptoms.
Claims (6)
1 . A method of reducing a symptom of an affective disorder or personality disorder in a subject, the method comprising administering to a subject having an affective disorder or personality disorder a an effective amount of a first agent selected from the group consisting of anipamil, devapamil, falipamil, gallopamil, tiapamil, and verapamil; and an effective amount of a second agent that is telmisartan or candesartan, wherein the symptom is selected from the group consisting of apathy, cognitive difficulty, depression, fatigue, headache, insomnia, irritability, and pain.
2 . The method of claim 1 , wherein the first agent is verapamil and the second agent is telmisartan.
3 . The method of claim 1 , wherein the effective amount of the first agent is from about 120 mg to about 720 mg and the effective amount of the second agent is from about 45 mg to about 180 mg.
4 . The method of claim 2 , wherein the effective amount of the first agent is 120-360 mg and the effective amount of the second agent is 40-180 mg.
5 . The method of claim 1 , wherein the method further comprises administering to the subject an effective amount of magnesium oxide.
6 . The method of claim 1 , wherein the first agent and the second agent are administered once or twice daily.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 17, 2024
From: SEIFAN, ALON
To: HONEYBRAINS, LLC
Reel/Frame 068009/0792 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 2, 2022
From: HONEYBRAINS, LLC
To: HB BIOTECH, INC.
Reel/Frame 061959/0960 →
Continuity (3)
Provisional Application
63111156
· Nov 9, 2020
Provisional Application
63011932
· Apr 17, 2020
References Cited (64)
US 6548529B1
· Robl et al.
· 2003
[cited by applicant]
US 6863901B2
· Hirsh et al.
· 2005
[cited by applicant]
US 20040248968A1
· Anderson
· 2004
[cited by examiner]
US 20040254176A1
· Grigorieff et al.
· 2004
[cited by applicant]
US 20050065094A1
· Davidai
· 2005
[cited by examiner]
US 20100137403A1
· Malstrom
· 2010
[cited by applicant]
US 20110269717A1
· Barlow et al.
· 2011
[cited by applicant]
US 20130210911A1
· Lee
· 2013
[cited by examiner]
US 20150098992A1
· Kim et al.
· 2015
[cited by applicant]
US 20150343067A1
· Gernot et al.
· 2015
[cited by applicant]
US 20200069583A1
· Gong et al.
· 2020
[cited by applicant]
US 20210186962A1
· Davis
· 2021
[cited by examiner]
CN 101890165A
· 2010
[cited by applicant]
CN 102266559A
· 2011
[cited by applicant]
CN 109010261A
· 2018
[cited by applicant]
EP 1870098A2
· 2007
[cited by applicant]
WO 2008141189A1
· 2008
[cited by applicant]
Nimmrich, V., and A. Eckert. “Calcium channel blockers and dementia.” British journal of pharmacology 169.6 (2013): 1203-1210. (Year: 2013).
[cited by examiner]
Saavedra, Juan M. “Evidence to consider angiotensin II receptor blockers for the treatment of early Alzheimer's disease.” Cellular and molecular neurobiology 36 (2016): 259-279. (Year: 2016).
[cited by examiner]
Hu, Ziheng, et al. “Synergism of antihypertensives and cholinesterase inhibitors in Alzheimer's disease.” Alzheimer's & Dementia: Translational Research & Clinical Interventions 4 (2018): 542-555. (Year: 2018).
[cited by examiner]
Tfelt-Hansen, Peer, and Jacob Tfelt-Hansen. “Verapamil for cluster headache. Clinical pharmacology and possible mode of action.” Headache: The Journal of Head and Face Pain 49.1 (2009): 117-125. (Year: 2009).
[cited by examiner]
Yablon, Lisa A., and Alexander Mauskop. “Magnesium in headache.” in Magnesium in the Central Nervous System (2011): 125-134. (Year: 2011).
[cited by examiner]
Clarke, Gerard, et al. “Verapamil in treatment resistant depression: a role for the P-glycoprotein transporter ?.” Human Psychopharmacology: Clinical and Experimental 24.3 (2009): 217-223. (Year: 2009).
[cited by examiner]
Li, Yingxiao, et al. “Telmisartan activates PPARδ to improve symptoms of unpredictable chronic mild stress-induced depression in mice.” Scientific Reports 7.1 (2017): 14021. (Year: 2017).
[cited by examiner]
Albayrak et al., “The Effects of Dual and Triple Combinations of Trandolapril, Telmisartan, and Verapamil on Overt Proteinuria in the Patients with Diabetic Nephropathy,” Saudi Journal of Kidney Diseases and Transplanta…
[cited by applicant]
Alzheimer's Drug Discovery Foundation, “Angiotensin II receptor blockers (ARBs),” Cognitive Vitality Reports, Jan. 23, 2019, pp. 1-12.
[cited by applicant]
Behjati, Mohaddeseh, “The concept of Maslow's pyramid for cardiovascular health and its impact on ‘change cycle’,” ARYA Atherosclerosis, 2014, vol. 10, No. 1, pp. 65-69.
[cited by applicant]
Brownstein et al., “Blockade of the angiotensin system improves mental health domain of quality of life: A meta-analysis of randomized clinical trials,” Australian & New Zealand Journal of Psychiatry, 2018, vol. 52, No.…
[cited by applicant]
Dorosch et al., “Efficacy of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the Preventative Treatment of Episodic Migraine in Adults,” Current Pain and Headache Reports, Sep. 12, 2019, vo…
[cited by applicant]
Dorsaint-Pierre et al., “Asymmetries of the planum temporale and Heschl's gyrus: relationship to language lateralization,” Brain, 2006, vol. 129, No. 5, pp. 1164-1176.
[cited by applicant]
Ha et al., “Migraine Headache Prophylaxis,” American Family Physician, Jan. 1, 2019, vol. 99, No. 1, pp. 17-24.
[cited by applicant]
Huffman et al., “Neuropsychiatric consequences of cardiovascular medications,” Dialogues in Clinical Neuroscience, 2007, vol. 9, No. 1, pp. 29-45.
[cited by applicant]
Kalra et al., “Combination therapy in hypertension: An update,” Diabetology & Metabolic Syndrome, 2010, vol. 2, Article No. 44, pp. 1-11.
[cited by applicant]
Modi et al., “Medications for Migraine Prophylaxis,” American Family Physician, Jan. 1, 2006, vol. 73, No. 1, pp. 72-78.
[cited by applicant]
Pan et al., “Association between anxiety and hypertension: a systematic review and meta-analysis of epidemiological studies,” Neuropsychiatric Disease and Treatment, Apr. 22, 2015, vol. 11, pp. 1121-1130.
[cited by applicant]
Pringsheim et al, “Systematic Review: Medications for Migraine Prophylaxis—Section II,” The Canadian Journal of Neurological Sciences, 2012, vol. 39, Suppl. 2, pp. S8-S28.
[cited by applicant]
Sareen et al., “Disability and Poor Quality of Life Associated With Comorbid Anxiety Disorders and Physical Conditions,” Archives of Internal Medicine, Oct. 23, 2006, vol. 166, No. 19, pp. 2109-2116.
[cited by applicant]
Seifan et al., “Childhood Learning Disabilities and Atypical Dementia: A Retrospective Chart Review,” PLoS One, Jun. 24, 2015, vol. 10, No. 6, e0129919, pp. 1-14.
[cited by applicant]
Zheng et al., “Safety Needs Mediate Stressful Events Induced Mental Disorders,” Neural Plasticity, 2016, vol. 2016, Article ID 8058093, pp. 1-6.
[cited by applicant]
International Search Report and Written Opinion mailed Jul. 20, 2021 in corresponding International PCT Patent Application No. PCT/US2021/027641 (9 pages).
[cited by applicant]
Imbrici et al., “Major channels involved in neuropsychiatric disorders and therapeutic perspectives,” Frontiers in Genetics, May 7, 2013, vol. 4, No. 76, pp. 1-19.
[cited by applicant]
Office Action dated Jun. 17, 2024 in corresponding Korean Patent Application No. 10-2022-7040160 (5 pages).
[cited by applicant]
English translation of Office Action dated Jun. 17, 2024 in corresponding Korean Patent Application No. 10-2022-7040160 (4 pages).
[cited by applicant]
Deicken, Raymond F., “Captopril treatment of depression,” Biological Psychiatry, 1986, vol. 21, pp. 1425-1428.
[cited by applicant]
Li et al., “Telmisartan Activates PPARδ to Improve Symptoms of Unpredictable Chronic Mild Stress-Induced Depression in Mice,” Scientific Reports, 2017, vol. 7, Article No. 14021, pp. 1-11.
[cited by applicant]
Saaby et al., “The putative p. gp inhibitor telmisartan does not affectthe transcellular permeability and cellular uptakeof the calcium channel antagonist verapamil in the P-glycoprotein expressing cell line MDCK II MDR…
[cited by applicant]
Vian et al., “The renin-angiotensin system: a possible new target for depression,” BMC Medicine, 2017, vol. 15, Article No. 144, pp. 1-13.
[cited by applicant]
Office Action dated Apr. 15, 2024 in corresponding Japanese Patent Application No. 2022-562964 (3 pages).
[cited by applicant]
English translation of Office Action dated Apr. 15, 2024 in corresponding Japanese Patent Application No. 2022-562964 (2 pages).
[cited by applicant]
Office Action dated May 3, 2024 in corresponding European Patent Application No. 21788923.7 (1 page).
[cited by applicant]
Extended European Search Report dated Apr. 15, 2024 in corresponding European Patent Application No. 21788923.7 (12 pages).
[cited by applicant]
Villapol et al., “Neurorestoration after traumatic brain injury through angiotensin II receptor blockage”, Brain, Nov. 2015, vol. 138, Part 11, pp. 3299-3315.
[cited by applicant]
Search Report dated Mar. 11, 2025 in corresponding Brazil Patent Application No. 1BR112022021011-6 (5 pages).
[cited by applicant]
Search Report and Office Action dated Mar. 25, 2025 in corresponding Brazil Patent Application No. BR122024007389-7 (7 pages).
[cited by applicant]
English Translation of Office Action dated Mar. 25, 2025 in corresponding Brazil Patent Application No. BR122024007389-7 (7 pages).
[cited by applicant]
Office Action dated Apr. 9, 2025 in corresponding Australian Patent Application No. 2021255701 (4 pages).
[cited by applicant]